Allos Works Toward Completion Of Merger With AMAG; Abbott rolls out U.S. clinical test. Print E-mail
By Staff and Wire Reports   
Monday, 10 October 2011 20:20
Below is a look at some of the headlines for companies that made news in the healthcare sector on October 10, 2011.

Allos Therapeutics, Inc. (NASDAQ:ALTH)
announced that it continues to work with AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), towards the completion of their merger, pending stockholder approval and satisfaction of the other conditions to closing described in Allos’ definitive proxy statement filed with the SEC on September 15, 2011.

On October 7, 2011, the publicly traded pharmaceutical company that had previously submitted a proposal to acquire Allos for $2.20 per share in cash and stock delivered a letter to Allos withdrawing its revised proposal to acquire Allos.

As a result, Allos is no longer providing information to, or engaging in discussions or negotiations with, that company with respect to the revised acquisition proposal or any other acquisition proposal.


Abbott Laboratories (NYSE:ABT) has enrolled its first United States patient for clinical testing of the Xience Prime stent. The testing program, called the Excel tests, will eventually involve some 2,600 patients at as many as 165 medical centers.

The patients in the tests will have medical problems involving blockages of their left main coronary arteries. Xience Prime is a stent developed and made at Abbott’s Temecula factory that is seen as an alternative to open heart surgery for people with that ailment.

The first patient enrolled into the Excel trial was at Turkey Creek Medical Center in Knoxville, Tenn., according to an Abbott statement. Xience Prime is already being used in Europe, Asia and Latin America.

Also Monday:

Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide (formerly known as Hematide™) have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that it continues to work with AMAG Pharmaceuticals, Inc. towards the completion of their merger, pending stockholder approval and satisfaction of the other conditions to closing described in Allos’ definitive proxy statement filed with the SEC on September 15, 2011.

Amarantus Biosciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class, disease-modifying therapeutic protein that addresses an underlying form of cell death known as apoptosis, announced today that it has completed a bridge facility with Atlantic Partners in the aggregate amount of $150,000.

BioTime, Inc. (NYSE Amex:BTX)
, a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D. will present at the GTC 2011 5th Advances in Stem Cell Discovery & Development Conference in San Diego, California at 9:10 a.m. PDT on Thursday, October 20, 2011.

Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), announced today that Medtronic Sofamor Danek USA, Inc., a global leader in medical technology, has selected the Callidus Monaco On Demand SPM suite to drive the performance of its sales organization nationwide.

eHealthInsurance (NASDAQ: EHTH), the leading online source of health insurance for individuals, families and small businesses, released a consumer checklist designed to help people with employer-sponsored health insurance find the best coverage for their needs during open enrollment season.

Electromed, Inc. (NYSE: ELMD)
, maker of the SmartVest® Airway Clearance System, announced today that it is expanding its product line with “Seriously Pink,” a new custom SmartVest color.

Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Pink: HFGB) ("Huifeng" or the "Company"), a Xi'an, China-based developer and producer of botanical extracts and other raw materials used in pharmaceuticals and food additives, today announced its subsidiary Shaanxi Huifeng Pharmaceutical Ltd. will attend the CPhI Worldwide Frankfurt 2011 in Germany.

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC)
(“ImmunoCellular” or the “Company”), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to ICT-107, the Company’s dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the clinical hold previously placed on Insmed's phase 3 clinical trials for ARIKACE® (liposomal amikacin for inhalation) in Cystic Fibrosis (CF) patients with Pseudomonaslung infections.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
announced today that it has entered into a global licensing agreement with Chiva Pharmaceuticals, Inc. for Fablyn (lasofoxifene), a selective estrogen receptor modulator (SERM) that was approved in the EU in 2009 for the treatment of osteoporosis in post-menopausal women at increased risk of fracture.

Marijuana Inc. (PINKSHEETS: PCIO)
announces its new symbol HEMP has been approved, thus signaling the aggressive launch of its various cannabis related industry divisions to be announced in upcoming press releases starting this week.

MMRGlobal, Inc. (OTCBB: MMRF), a leading provider of Personal Health Records, MyEsafeDepositBox storage solutions and electronic document management systems for healthcare professionals, today announced it is expanding its international footprint with Chairman and CEO Robert H. Lorsch accepting an invitation to meet with H.H. the Amir Sheikh Hamad Bin Khalifa Al-Thani of Qatar and visit Qatar Science & Technology Park (QSTP) with the purpose of discussing investment opportunities to introduce MMR's signature, patented Personal Health Record products ( and MMRPro professional solution for physicians and hospitals ( in the Middle East.

Nanostart (OTCQX:NASRY)-holding MagForce AG (FSE: MF6), a leading medical technology company focusing on nanomedicine in oncology, announced today the treatment of a recurrent glioblastoma patient with the company’s NanoTherm® therapy.

Natus Medical Incorporated (Nasdaq:BABY) today announced that it expects to report revenue for the third quarter of 2011 of approximately $51.5 million, including approximately $1.5 million from Embla Systems, which the Company acquired on September 15, 2011.

Nuvilex, Inc. (OTCQB: NVLX) announced today substantial testing has been completed and more testing is underway combining its patented encapsulation technology with live stem cells.

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer’s disease., Inc. (PINKSHEETS: SEEK) today announced that the Company continued its positive operating trend by turning a profit for the month of September.

United Therapeutics Corporation (NASDAQ: UTHR) announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit!! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus